Pediatric Clinical Year in Review: 2023

Samantha C. Shapiro, MD, is the executive editor of Harrison’s Principles of Internal Medicine. As a clinician educator, she practices telerheumatology and writes for both medical and lay audiences.

References

1. Ramanan AV, Quartier P, Okamoto N, et al. Baricitinib in juvenile idiopathic arthritis: An international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023 Aug 12;402(10401):555–570.
2. De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023 Jun;82(6):857–865.
3. Curiel R V., Nguyen W, Mamyrova G, et al. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023 Jul;75(7):1229–1237.
4. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023 Mar;75(3):449–464.
5. Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: Update 2021. Ann Rheum Dis. 2023 Jan;82(1):35–47.
6. Bingham CA, Harris JG, Qiu T, et al. Pediatric Rheumatology Care and Outcomes Improvement Network’s quality measure set to improve care of children with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2442–2452.
7. Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 Oct;82(10):1271–1285.
8. Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis–associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2023 May;75(5):975–982.
9. Wobma H, Bachrach R, Farrell J, et al. Development of a screening algorithm for lung disease in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2023 Oct;5(10):556–562.
10. Delcoigne B, Horne AC, Reutfors J, Askling J. Risk of psychiatric disorders in juvenile idiopathic arthritis: Population- and sibling-controlled cohort and cross-sectional analyses. ACR Open Rheumatol. 2023 May;5(5):277–284.
11. Li L, Merchant M, Gordon S, et al. High rates of symptoms of major depressive disorder and panic disorder in a Canadian sample of adolescents with juvenile idiopathic arthritis. J Rheumatol. 2023 Jun;50(6):804–808.
12. Nguyen K, Barsalou J, Basodan D, et al. A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: Results from ReACCh-Out and the CAPRI registry. Rheumatology (Oxford). 2023 Oct 18:kead560.
13. Collado P, Martire MV, Lanni S, et al. OMERACT international consensus for ultrasound definitions of tenosynovitis in juvenile idiopathic arthritis: Systematic literature review and delphi process. Arthritis Care Res (Hoboken). 2023 Nov;75(11):2277–2284.
14. Vega-Fernandez P, Oberle EJ, Henrickson M, et al. Musculoskeletal ultrasound and the assessment of disease activity in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2023 Aug;75(8):1815–1820.
15. Vega-Fernandez P, Esteban Y, Oberle E, et al. Reliability of the pediatric specific musculoskeletal ultrasound scoring systems for the elbow, wrist, and finger joints. Journal of Rheumatology. 2023 Feb;50(2):236–239.
16. Reiff DD, Bridges JM, Rife EC, et al. Majority of new patient referrals to a large pediatric rheumatology center result in non-rheumatic diagnosis. Pediatr Rheumatol Online J. 2023 Oct 13;21(1):120.